



#### The Norwegian Breast Cancer Screening Program

(NBCSP)

Berit Damtjernhaug Head of NBCSP

The Cancer Registry of Norway
Institute of Population-Based Cancer Research, Oslo, Norway








> The Cancer Registry of Norway and some statistics

> Organization and logistics of the NBCSP

> Results of Early Outcome and Selected Process Indicators







#### The Cancer Registry of Norway

- > Established in 1951
- > Nationwide, population based
- Mandatory by law to report all new cancer cases, without consent
- > Primary goal is the establishment and dissemination of new knowledge which contributes to the reduction of cancer.
- > 225 000 notifications related to cancer illness every year. Of these, almost 25 000 are newly diagnosed
- > Screening programs:


Breast Cervix





#### The most frequent incident cancers 2003-2007


#### FEMALES all ages (59 258 cases)









### Incidence of invasive breast cancer in Norway (all ages, not age adjusted)




# Incidence of breast cancer – 5 year age groups 1990-94



# Incidence of breast cancer – 5 year age groups 1990-94 and 2006




#### Incidence of breast cancer in Norway








# Relative survival from breast cancer diagnosed 1990-94, all ages



#### Mortality from breast cancer 1953-2003

#### Age adjusted rates











The Norwegian Breast Cancer Screening Program (NBCSP)



#### **NBCSP**

> Start: 1995 in 4 pilot counties (40% of the target population)


> Expansion: 1998

Nationwide: 2004

> Owned by the Health Authorities

- > Managed by the Ministry of Health and Care Services
- > Administered by the Cancer Registry of Norway
- > Co-operation between:
  - > The Cancer Registry of Norway (administration)
  - > The Norwegian Institute of Public Health
  - > The Norwegian Radiation Protection Authority
  - > The Health Trusts/counties
- National Advisory group: quality assurance
  - > Different professions
  - Quality assurance manual





www.kreftregisteret.no





#### **NBCSP**

Population registry: 11-digit number

Target population: 50-69 year, 500 000 at the time being

Invitation: Personal letter,

Own risk: 25 Euro/ 40 US\$

Screening procedures: 32 stationary and mobile units, 12/hour

Work up: at 17centralized breast units (breast centers)

Two-years screening interval, two views

Double independent reading

Coding and reports: All units report all activity to the Mammography


database at the Cancer Registry

Quality assurance: Quality assurance manual

The Norwegian Radiation Protection Authority











#### **NBCSP - Organization**

















#### IT-system: Flow chart







#### **NBCSP - Invitation**







#### **NBCSP**

The aim is to reduce breast cancer mortality by 30% among the invited women





#### **NBCSP**

Intermediate indicators are developed to measure effect of performance on service screening programs:

- Attendance rate
- Recall rate
- Detection rate
- Stage and morphological caracteristics
- •Interval cancer






#### Attendance


	Prevalent round	Subsequent round	Total
Total attendance	76,5 %	76,7 %	76,6 %
- Stationary units			75,8 %
- Mobile units			79,6 %

	Prevalent round	Subsequent round	Total
City*	73,8 %	69,4 %	70,1 %
Rural**	86,8 %	84,3 %	84,7 %





#### Attendance in age cohorts







#### Recall and screen detection rates

	Prevalent screens N=488,696	European guidelines	Subsequent screens N=570,613	European guidelines
Recalls (n, %)	22,275 / <b>4.6</b>	< 5.0	14,723 / <b>2.6</b>	< 3.0
Screen cancers (n, %)	3,168 / <b>0.6</b>		2,810 / <b>0.5</b>	
Screen detection rate of invasive cancers / background incidence	534 / 180 <b>3.0</b>	> 3.0	408 / 180 <b>2.3</b>	> 1.5





### Prognostic tumor characteristics in invasive screen detected breast cancer

	Prevalent screens N=2,609	European Guidelines	Subsequent screens N=2,326	European Guidelines
Tumor size				
Mean (mm)	15.2		14.1	
Median (mm)	13		12	
≤ 10mm (%)	34.3	≥ <b>25</b>	30.7	≥ <b>30</b>
< 15mm (%)	53.9	> 50	61.3	> 50
> 20mm (%)	18.4	< 25	15.6	< 20
Unknown (n)	88		102	
Grade				
1 (%)	38.0		34.3	
2 (%)	47.8		48.5	
3 (%)	14.2		17.2	
Unknown (n)	139		110	
Axillary lymph node metastasis				
No metastases (%)	74.1	> 70	75.2	> 75
Unknown (n)	131		199	
Hormone receptor status				
Estrogen positive (%)	88.8		86.3	<b>L</b> FI
Unknown (n)	331		316	Service
Progesterone positive (%)	69.5		65.5	WW
Unknown (n)	362		360	W

# Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program Hofvind S, Sorum R, Thoresen S. Acta Oncol. 2007 Sep 12;:1-7

Tumor size	Before screening	Invited	Not invited	Exposed	Not exposed
≤ 20mm	778 (55.7)	2,561 (74.3)§	268 (63.8)§	2,244 (76.8)§	585 (61.8)§
> 20 ≤ 50mm	463 (33.2)	745 (21.6)§	122 (29.0)§	584 (20.0)§	283 (29.9)§
> 50mm	53 ( 3.8)	56 ( 1.6)§	12 ( 2.9)	41 ( 1.4)§	27 ( 2.9)
Grown into chest-wall, cutis	102 ( 7.3)	85 ( 2.5)§	18 ( 4.3)§	51 ( 1. <b>7</b> )§	52 ( 5.5)
No information	1, 138	610	165	471	304



Data from Akershus, Hordaland, Oslo and Rogaland. Before screening: 1987-1995, screening period: 1996-2004



#### Interval cancer detection rates

(Hofvind et al, Eur J Epi, 2007)

	Prevalent screens (n=448,696)	Subsequent screens (n=570,613)	
DCIS	0.17	0.12	
Invasive DCIS + invasive (per 1000 screens)	1.65 1.72	1.69 1.81	






### Histological prognostic factors in invasive screen detected and interval cancers diagnosed in the NBCSP 1996-2005


	Screen	Interval	Chi-
	detected	cancer	square
	N=4,945	N=1,173	
Tumor size	,	, -	
Mean (mm)	14.7	21.2	< 0.001
Median (mm)	13	18	
Unknown (n)	190	117	
Grade			
1 (%)	36.2	20.7	< 0.001
2 (%)	48.2	48.6	
3 (%)	15.6	30.6	
Unknown (n)	249	63	
Axillary lymph nodes			
Negative (%)	74.6	56.2	< 0.001
Unknown (n)	330	180	
Hormonal status			
Estrogen positive (%)	87.6	73.6	< 0.001
Unknown (n)	647	155	
Progesterone positive (%)	60.6	53.0	< 0.001
FT Unknown (n)	722	178	S. A.F
			<0.001

Hofvind et al, Eur J Epidemio DOI 10.1007/s10654-9137-y

#### Interval cancer – When do they appear?




# Surgery treatment of breast cancer in the pre-screening and screening period





#### Use of Sentinel Node Technique

(AHOR,50-69 years old, 1993-2004)





Okt06

#### Evaluation of the NBCSP

The Ministry of Health and Care Services has charged the Research Council of Norway with responsibility for conducting a research-based evaluation of the Norwegian Breast Cancer Screening Program.

The objective is to investigate whether the program has fulfilled its intentions and purpose, with special weight on mortality-reduction.







